Tag: Erythropoietic Protoporphyria
-
LEO Pharma Bets Up to $435 Million on Oral Therapy for Rare Sunlight-Induced Pain
LEO Pharma is acquiring global rights to dersimelagon from Tanabe Pharma in a deal worth up to $435 million. The oral MC1R agonist has completed Phase 3 development in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) and has already been submitted to the FDA.
-
Three Different Ways to Reduce Phototoxic Pain in EPP and XLP
Dersimelagon, Scenesse and bitopertin approach phototoxic pain through fundamentally different strategies. This BP Science explainer compares MC1R-driven photoprotection with upstream reduction of protoporphyrin IX (PPIX) production in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP).